SATB1 and prostate carcinoma: Similarly, LMNA repositioned in 36.4% (4/11), SATB1 in 34.8% (8/23), and TGFB3 in 31.8% (7/22) of prostate cancer tissues (Figure 1, Table 1, Supplementary Tables 3–5).